Current Medicare policies do not adequately reimburse cancer care provided in the community setting, the Community Oncology Alliance and the U.S. Oncology Network said in a joint, open letter to members of Congress.
Cancer research remains underfunded, and the U.S. cancer care system as a whole may be unprepared to handle an aging population, according to two separate reports from the American Association for Cancer Research and the American Society of Clinical Oncology.
The chairs of the adult clinical trials groups that make up the NCI National Clinical Trials Network said in a letter that recent budget cuts have triggered a “crisis” in clinical research.
Sometimes a funding increase can be no increase at all.
Addressing the Molecular and Genetics Screening Panel, David Ransohoff, coauthor of the NEJM paper, focused on the future role of noninvasive tests like Cologuard in programs of screening for colorectal cancer.
The Panel's Comments“I typically refrain from commentary, but I will say this: I think this is a phenomenal study, in particular, for one reason,” said FDA panel member Ronald Przygodzki, acting director of Biomedical Laboratory Research and Development at the Department of Veterans Affairs Office of Research & Development.
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
I don't see the American Cancer Society on the list. I don't see…
Ella KazerooniThe Cancer Letter asked Ella Kazerooni, a professor of radiology at the University of Michigan, chair of the American College of Radiology Committee on Lung Screening, and vice chair of the lung screening panel of the National Comprehensive Cancer Network, to lay out the rationale for a proposal for broad coverage for lung screening.
Beyond NLST Findings and USPSTF GuidelineThe 40 groups petitioning CMS are seeking to broaden the eligible population further to “other high risk patient populations where evidence is promising.”
